Almirall, S.A. (ALMRY) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank standing by. Welcome to the Almirall First Quarter twenty twenty six Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Pablo Di Vason, Head of Investor Relations. Please go ahead. Thank you very much, Matalena. Good morning, everyone. Thank you for joining us for today's quarterly earnings update and review of Almirall first quarter financial results for 2026. As always, we are sharing the slides we are using today in the Investors section of almirall.com. Please move to Slide number two. Let me remind you that the information presented in this call contains forward looking statements, which involve known and unknown risks, uncertainties and other factors that may cause actual results to materially differ from what we are sharing today. Please move to Slide three. Presenting today, we have Carlos Gallardo, Chairman and Chief Executive Officer John Garai, Chief Financial Officer and Carl Sighabar, Chief Scientific Officer. Carlos will start with the business highlights of the first quarter, followed by an update on biologics as the key growth drivers of our medical dermatology portfolio. Carl will provide you with an update on the pipeline and R and D programs. John will then walk you through the financials before Carlos concludes the presentation and we open for questions. I will hand over to Carlos Gallardo, our Chairman and CEO. Please move to Slide number five. Thank you, Pablo, and good morning to everyone in the call. Almirall delivered steady performance in line with our expectations and market consensus in the first q...